The management of Type 2 Diabetes (T2D) remains a significant challenge for patients and healthcare providers worldwide. For many individuals experiencing poor glycemic control, the introduction of insulin therapy typically marks a pivotal aspect of their treatment plan. However, the often burdensome nature of multiple daily injections hampers both the timely initiation and adherence to insulin treatments. Enter insulin icodec, a once-weekly basal insulin offering a potential solution to these challenges. This study investigates its cost-effectiveness compared to traditional long-acting basal insulins in a Canadian context, heralding promising outcomes for adults living with T2D.
Study Objectives and Methods
Aiming to evaluate insulin icodec against conventional basal insulins including insulin glargine, insulin detemir, and insulin degludec, the research utilized the T2D Cohort Model from the Swedish Institute of Health Economics. Participants were categorized into three groups: insulin naïve (IN), basal insulin experienced (BIE), and basal-bolus insulin experienced (BBIE). The analysis incorporated data from the ONWARDS trials and employed network meta-analyses (NMA) over a projected horizon of 40 years. Factors such as potential vascular complications, demographics, diabetes history, and frequency of hypoglycemia were accounted for, with an annual discount rate of 1.5% applied across cost and effect metrics.
Research Findings
Research findings revealed that insulin icodec showed a cost-effective profile, presenting dominance over insulin degludec and detemir. When compared to insulin glargine, insulin icodec’s incremental cost utility ratios (ICURs) were measured at $17,876, $20,844, and $73,253 for the IN, BIE, and BBIE groups, respectively. For the Canadian market, outcomes were expressed in quality-adjusted life-years (QALYs) and took into account market share variations and the availability of biosimilars.
Key inferences drawn from the study include:
- Insulin icodec offers a reduction in injection frequencies.
- Economic feasibility aligns with improved patient quality of life.
- A robust comparison against multiple basal insulins consolidates icodec’s efficacy.
Insulin icodec stands out as a cost-effective treatment to manage Type 2 Diabetes effectively while improving the quality of life for patients. Its once-weekly regimen decreases the barriers associated with frequent injections, thus fostering better adherence. However, this analysis also unveils certain limitations, notably the dearth of comprehensive treatment data in NMAs and the uncertainty surrounding extended use over 40 years. Additionally, it sheds light on the heterogeneous nature of disentangling health-related quality of life benefits when dealing with reduced injection frequencies. Overall, insulin icodec’s economic advantage could substantially benefit the Canadian public health framework, suggesting a potential paradigm shift in how diabetes care might be approached moving forward.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
